TY - JOUR
KW - Analgesics, Opioid/adverse effects/therapeutic use
KW - Buprenorphine/therapeutic use
KW - Clinical Trials as Topic
KW - Diffusion of Innovation
KW - Evidence-Based Medicine
KW - Humans
KW - Opioid-Related Disorders/rehabilitation
KW - Substance Abuse Treatment Centers/organization & administration
KW - United States/epidemiology
AU - L. J. Ducharme
AU - P. M. Roman
A1 - 
AB - As the Clinical Trials Network (CTN) begins to focus efforts on disseminating the results of its research studies to the addiction treatment field, it is important to begin to assess the capacity of programs outside the CTN to integrate with fidelity these endorsed treatment practices. To date, no data exist to assess the representativeness of opioid treatment programs (OTPs) participating in the CTN, nor potential barriers to the effective diffusion of practices aimed at the treatment of opioid-dependent patients, including buprenorphine. Using data obtained from OTPs within the CTN (n = 49) and a sample drawn from the population of U.S. OTPs (n = 50), this study compares the two groups on their organizational, clinical, and client characteristics, as well as their adoption of buprenorphine. The study finds that the populations differ significantly on numerous variables but that structural characteristics appear more predictive of buprenorphine adoption than either staff or caseload differences. Implications for studying the diffusion and implementation of evidence-based research findings are discussed.
BT - Journal of substance abuse treatment
C5 - Opioids & Substance Use
CP - 1
CY - United States
DO - 10.1016/j.jsat.2008.09.003
IS - 1
JF - Journal of substance abuse treatment
N2 - As the Clinical Trials Network (CTN) begins to focus efforts on disseminating the results of its research studies to the addiction treatment field, it is important to begin to assess the capacity of programs outside the CTN to integrate with fidelity these endorsed treatment practices. To date, no data exist to assess the representativeness of opioid treatment programs (OTPs) participating in the CTN, nor potential barriers to the effective diffusion of practices aimed at the treatment of opioid-dependent patients, including buprenorphine. Using data obtained from OTPs within the CTN (n = 49) and a sample drawn from the population of U.S. OTPs (n = 50), this study compares the two groups on their organizational, clinical, and client characteristics, as well as their adoption of buprenorphine. The study finds that the populations differ significantly on numerous variables but that structural characteristics appear more predictive of buprenorphine adoption than either staff or caseload differences. Implications for studying the diffusion and implementation of evidence-based research findings are discussed.
PP - United States
PY - 2009
SN - 1873-6483; 0740-5472
SP - 90
EP - 94
EP - 
T1 - Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption
T2 - Journal of substance abuse treatment
TI - Opioid treatment programs in the Clinical Trials Network: representativeness and buprenorphine adoption
U1 - Opioids & Substance Use
U2 - 19004597
U3 - 10.1016/j.jsat.2008.09.003
VL - 37
VO - 1873-6483; 0740-5472
Y1 - 2009
ER -